Amphotericin B (AmB) is a large amphiphilic molecule, which is a drug of choice in therapy of systemic fungal infection because of its board-spectrum antifungal activity. However, conventional formulation of AmB is micelles, which is unstable in the bloodstream and releases drug to form toxic aggregates. Lipid complex of AmB has been developed to reduce toxicity while retaining activity. Microfluidic method is mixing technique, which permits millisecond mixing at the nano/microliter scale, can reproducibly generate limit size of particles of drug delivery system. In this study, microfluidic hydrodynamic focusing method was used to produce AmB lipid complex. It was obtained of two synthetic phospholipids: hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylglycerol (DSPG) and AmB in the molar ratio of 1:1:2.The lipid complex of AmB was characterized using differential scanning calorimetry (DSC), X -ray diffraction, Fourier-transform infrared spectroscopy (FTIR) and Field Emission Scanning Electron Microscopy(FESEM).The results showed that AmB lipid complex, prepared by microfluidic method, had smallest size at the flow rate ratio (FRR) of 5:1. The distinct phase transition temperature, the crystal peak of phospholipid, the characteristic band of-P-O-group of phospholipid were not observed in the DSC curve, X-ray diffraction diagram and FTIR spectra, respectively, of AmB lipid complex.
INTRODUCTION
Amphotericin B (AmB) is a large amphiphilic molecule, which is a drug of choice in therapy of systemic fungal infection because of its board-spectrum antifungal activity 1 . In addition, studies have shown that it is also effective in the treatment of visceral leishmaniasis 2 . Since AmB is insoluble in water, conventionally, it was solubilized and formulated in deoxycholate forming micelles. However micelles are unstable in the bloodstream, releasing drug to form toxic aggregates, that may cause side effects including fever, nausea, vomiting, lysis of red blood cells and nephrotoxicity 3 .
To reduce the toxic effects of AmB, several lipid-based formulations were developed and compared with the conventional form. In general, lipid complex of AmB were shown to be less toxic than deoxycholate formulation while retain activity 4 . Microfluidic method is a mixing technique, which permits millisecond mixing at the nano/ microliter scale, can reproducibly generate limit size of particles of drug delivery system 5 . Thus, microfluidic systems have been increasingly used for fabrication of drug carriers such as liposomes, polymer nanoparticles, emulsion etc. [6] [7] [8] [9] [10] [11] . In microfluidic technology, continuous and multiphase fluidic systems are usually used for production of drug carrier 12 . However, among these, the microfluidic hydrodynamic focusing (MHF) approach presents the typical physical *Corresponding author: phamminhhuehup@gmail.com characteristics of microfluidic systems (i.e., including low Reynolds number and diffusion dominated mass transfer) and represents the suitable microfluidic method for producing lipid-based systems with potential for clinical application 13 . This hydrodynamic flow focusing method squeezes a solvent-lipid solution and aqueous phase into a very narrow central. The narrow width of the focused stream and laminar flow in the channel enables rapid mixing through molecular diffusion at the liquid-liquid interface where the lipids self-assemble into vesicles or lipid complexes 14, 15 . In this study, we prepared lipid complex of AmBby microfluidic hydrodynamic focusing flow method. AmB lipid complex was obtained of two synthetic phospholipids: hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylglycerol (DSPG) and AmB in the molar ratio of 1:1:2. Influence of the flow rate ratio (FRR) of aqueous to solvent-lipid phases on particle size and size distribution was evaluated. The physicochemical characterization of AmB lipid complex was systematically investigated by Fourier transform infrared spectrometry (FTIR), differential scanningcalorimetry (DSC), powder X-ray diffraction (PXRD) and field emission scanning electron microscopy (FESEM).
MATERIALS AND METHODS

Materials
Amphotericin B was purchased from Ningbo Honor Chemtech Co.,Ltd (China); hydrogenated soy phosphatidyl choline and distearoylphosphatidyl glycerol -Avanti Polar Lipid (US); chloroform was purchased from RCI Labscan Limited (Thailand); ethanol was purchased from DG chemical (Vietnam); acetonitril and methanol for HPLC were purchased from J.T. Baker Avantor (US).
Method preparation of AmB lipid complex
Microfluidic hydrodynamic focusing (MHF) method: AmB was dissolved in the ethanol, acidified by HCl solution of 2.5 N to pH of 0.5-1.0 (solution 1). HSPC and DSPG in the 1:1 molar ratio were dissolved in the solvent mixture of chloroform and ethanol (1:1, v/v) to form solution 2. Solution 1 wasmixed with solution 2 to form solvent-lipid phase 16 . Aqueouse phase was 0.9% sodium clorid solution. MHF device used in the studyisshown in the Figure 1 , which is similar to the device in the reference 17 . Solvent and aqueous phases were heated to 65 o C using a water bath before mixing. Solvent-lipid phase was injected through 23G needle (internal diameter was 0.6414 mm) into the connector of MHF device using a peristaltic pump. Aqueous phase was injected into the conector through the tubing with internal diameter of 1mmby peristaltic pump. The internal diameter of the outlet of connector was 2mm. The mixture was evaporated under reduced presure to remove ethanolfor AmB lipid complex suspension production. Purification: prepared suspension of AmB lipid complex was purified and concentrated by crossflow system (SARTOFLOW® Slice 200 Benchtop, Germany) until determined concentration of AmB (5mg/ml) using 30 kDa polyethersulfone membrane (Satorius Stedium biotech GmbH, Germany).
Drying: Suspension of AmB lipid complex was dried in the vacuum oven at 40 o C for 48 h for DSC, XRD and FTIR characterization. Dry samples were stored in the refrigerator at 2-8 o C.
Preparation of physical mixture and placebo sample
physical mixture was prepared by mixing AmB, HSPC and DSPG in molar ratio of 1:1:2 thoroughly for 10 min in a mortar until a homogenous mixture was obtained. The sample was passed through 40# mesh.
Placebo sample was prepared by MHF methods using device in "Method preparation of AmB lipid complex" using only HSPC and DSPG. Suspension of placebo sample was dried in the vacuum oven at 40 o C for 48 h to use in the XRD and FTIR investigations.
AmB lipid complex characterization
Size analysis
Particle size and distribution of particle size were evaluated by laser diffraction using Mastersizer 3000 E (Malvern, UK). Each sample was diluted with purified water, filtered through membrane with pore size 0.22 µm, until laserobscuration is in the range 3 -20%. The parameter Span is an indicator of the particle size distribution of the sample. The smaller Span shows narrower range of distribution.
Determination of AMB content
Quanlitative and quantitative analysis of AmB in lipid complex were performed by High-perfomance liquid chomatography (HPLC). The analytical column was RP 5C18-MS-II 250x4.6 mm (Cosmosil, Japan), operation was carried out at ambient temperature. The mobile phase was a mixture of acetonitril and 0.002M solution of disodium edetat (pH 5.0) in a ratio of 40:60 (v/v), the flow rate was 0.8 ml/min, detector was UV visible at 405 nm. Lipid complex suspension was dissolved with mixtured solvent methanol:chloroform (3:1, v/v), then diluted with solution of acetonitril : 0.002M disodiumedetat (pH 5.0) in a ratio 60:40 (v/v). The sample was filtered through 0.45 µm membrane prior to injection to the column. Under the HPLC condition, retention time of AMB was 6.3 min. HPLC linearity was determined from 6 working standard solutions of AmB. The HPLC method for quantitation of AmB in samples was validated. The calibration curve showed good linearity relationship in the range of 10-100 μg/ml (r 2 =0.999). The LOD and LOQ were 3.24 and 9.82 μg/ml, respectively. The evaluation of system suitability, precision parameters were also found to produce satisfactory results.
Differential scanning calorimetry (DSC)
Thermal behavior of selected AmB lipid complex samples was characterized through Mettler Toledo calorimeter (Switzerland). Approximately, 5 mg of solid sample were sealed in an aluminum pan and transferred in the calorimeter. Data were recorded as formulations which were heated at 10°C/min from 40°C to a final temperature of 200°C.
X-ray diffraction (XRD)
The crystalline state of drug in the different samples was evaluated with X-ray powder diffraction. Diffraction patterns were obtained on a Bruker Axs-D8 Discover Powder X-raydiffractometer (Germany). The scanning angle ranged from 10 to 50 o of 2θ in step scan mode (step width 1 o /min).
Fourier transform infrared spectroscopy
Infra-red spectra were prepared using a Nicolet Magna spectrometer (USA). Thin tablets were produced through pressing approximately 2 mg dry sample 200 mg KBr under pressure of 6-7 T. The dry samples were calculated applying Jasco Spectra Manager® software (USA). The scale range of wave number was adjusted in 4000-400 cm -1 with resolution 0.4 cm -1 .
Morphology
Morphology of AmB lipid complex was observed by Field Emission Scanning Electron Microscope (FESEM S4800, Hitachi, Japan). The sample was put on a plate, continued drying with vacuum oven at 40 o C for 48 h. The dried sample was coated with gold and observed in the FESEM S4800 (Hitachi, Japan).
Stability of suspension of AmB lipid complex
The concentrated suspension of AmB lipid complex (5mg/ml) and non-concentrated suspension was stored in the refrigerator (at 2-8 o C). After determined periods of time, the size of lipid particles was evaluated.
Statistical analysis
Data were expressed as the mean ± standard deviation (SD) of the mean, and statistical analysis was based on the p-value, p-value < 0.05 was considered statistically significant difference. Table 1 shows the relationship of particle size vs. flow rate ratio (ratio between aqueous and solvent streams). It is clearthatwhen FRR increased, average size (D [4, 3] ) of particles decreased. The largest mean size of AmB lipid complexwas 33.1 µmatFRR of1:3.2. In contrast, the smallest lipid complex particles(mean diameter =3.4µm) was producedat FRR of 7:1. The combination between the decrease of particle size due to increase of FRR confirms previous studies in the literature [18] [19] [20] . However, increasing flow rate ratio increased polydispersity. The impact of flow rate ratio on distribution are in agreement with previous work showing that the increase in FRR widen the distribution range of the particles 19 . When the flow rate ratio was higher than 5, polydispersity strongly increased; at the highest FRR (6:1-formulations F8 and 7:1 -formulation F9) Span value were highest (10.1 and 10.3, respectively). This phenomena should be explained that, at very high flow rate ratio, velocity of aqueous flow was higher than solvent phase by 6 or 7 fold, that push back the solvent flow, leading to the not well mixing phases in the connector. As the data showed, the FRR of 5:1 (Formulation F7) produced small lipid complex particle with narrow distribution; 6.5 µm and 2.25, respectively. 
RESULTS AND DISCUSSION
Evaluation of flow rate ratio
Stability of suspension of AmB lipid complex
In this experiment, size of AmB lipid complex particle was reduced from 6.2 µm to 0.8 µm after purification (see Table 2 ). The polyethersulfone membrane (30 kDa) using in the crossflow system permits particles or molecules, smaller than 30 kDa, pass through. The waste liquid was yellow and transparent, indicated present of AmB. In addition, the processing yield before purification was 89.6±3.5% and after purification -78.9±2.5%. Therefore, about 10% drug was filtrated from complex suspension after purification, filtrated AmB should be micellar form (because of transparent waste liquid). Thus, decreasing size of complex in the crossflow system should be explained by shortening the ribbon like structure, composed of cylinders of AmB and phospholipid in the molar ration of 1:1 21 . Particle size rapidly increased in the diluted solution (p-value < 0.05), from 6.2 µm at start moment increased to17.6 µm after 2 months storage. By contrast, the changed of particles size and Span of concentrated suspension after 2 months storage was not statistically significant difference with p-value >0.05, particle size changed from 0.833 to 0.901 µm, Span value increased from 4.01 to 4.67. In this study, AmB lipid complex in the concentrated suspension (5 mg/ml of drug concentration) was more stable than in the more diluted suspensions. This phenomena should be explained by forming flocculation, which stabilized particle size of complex in the concentrated suspension. o C corresponding to pre-transition and phase transition temperature, respectively. The DSC curve of AmB lipid complex showed that original peaks of phospholipids and drug have disappeared. The significant difference of DSC graphs among four samples indicated that the AmB and phospholipids in the complex were amorphous. All the results suggested that some weak interactions, such as the hydrogen bonds or Vander Waals force are formed between AmB and phospholipid molecules [22] [23] [24] [25] [26] . o indicating its crystalline characteristics. There is still an apparent diffraction peak at 21.5 o in the sample Physical mixture and placebo. By the contrast, the crystalline peaks had disappeared in the complex compared with that of the physical mixture and placebo. It is presumed that a directional combination happened between AmB and phospholipids during the complex forming process. Therefore AmB and phospholipids actually stay in a highly dispersed state, resulting in the masking of their own crystalline characteristics. Figure 4 presents the IR spectra of DSPG, HSPC, AmB, Physical mixture, placebo sampleand AmB lipid complex. The AmB spectrum ( Figure  4F ) exhibits board OH peaks at 3472.20 cm -1 , characteristic peak of C=O at 1691.25 cm
DSC
X-ray diffraction
FTIR
The board peak at 3472.20 cm-1 show intermolecular hydrogen bond 27 . The DSPG spectrum ( Figure 4A) Figure 4E ) probably due to weakening or removing. This phenomenon could be due to electronic bond between group NH 3 + of AmB and P-O-of phospholipids.
The peak at 1735.65 and 1718.22cm-1 (C=O stretching) were retained in the physical mixture but changed in the lipid complex, indicating their involvement in the formation of the complex. This could be due to hydrogen bond between C=O of AmB and O-H groups of phospholipid. The peaks at 1238.51 cm -1 (P=O stretching) of the phospholipids were retained in the physical mixture, placebo sample and in the complex, indicating their non-involvement in the formation of the complex. The board peak at 3472.20 cm -1 of O-H bond in AmB molecule disappeared in the lipid complex and physical mixture showed that quantity of C-H bonds is more than the O-H bonds and intensity of C-H bond overwhelms intensity of O-H bond.
FESEM
The FESEM images of AmB lipid complex were shown in the Figure 5 . The FESEM images of AmB lipid complex are given in Figure 5 . As observed in Figure 5 , AmB lipid complex existed as ribbon like structure. This morphology of AmB lipid complex coincides with the morphology of the lipid complex, prepared by bulk method 28 . Although AmB lipid complex in our study obtained of HSPC and DSPC, differed from excipients of commercial AmB lipid complex (dimyristoylphosphatidylcholine -DMPC and dimyristoylphosphatidylglycerol -DMPG), but both lipid complexes had similar morphology 21 .
CONCLUSION
Our present work might provide some new insights and paradigms for production of phospholipid complex using microfluidic method. We have demonstrated a high-throughput, robust method of preparing size-controlled lipid complex using microfluidic simple and reproducible hydrodynamic flow focusing method. The complex formation of AmB lipid complexwas proven by FTIR, DSC, PXRD, and FESEM. All studies showed that drug and phospholipid combined and formed complex.
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